Fluvastatin Sodium Articles
Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential
23 February 2009
Rx-to-OTC switching making comeback
21 April 2008
Doctors claim statins cause memory loss
25 February 2008
Japan stock market week to Jan 21, 2008
28 January 2008
Meta-analysis in The Lancet recommends statins for all diabetics, regardless of CV risk
21 January 2008
ALERT study confirms Lescol safety
13 September 2004
Amylin to co-promote Reliant cardiovasculars
19 April 2004
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
Novartis' Lescol useful in renal transplantation
16 June 2003
New use for Novartis' statins
2 June 2003
Novartis seeks new indication for Lescol in USA
12 August 2002
Update: Alkermes to acquire Reliant in $934M deal
1 April 2002
Lescol cuts cardiac events after PCI
25 March 2002
Alkermes to acquire Reliant in $934M deal
25 March 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Double-digit turnover growth for Novartis
11 October 2001
French price cuts for GSK, Lilly, Merck drugs
16 August 2001
Morepen looks to grow in the USA
2 February 2001
Stroke prevention emerges from heart disease
10 January 2001
Novartis wins FDA OK for new Lescol formulation
10 October 2000
Promising Ph III data with Novartis' Lescol XL
29 June 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Novartis seeks OK for Lescol extended-release
16 December 1999
Novartis upbeat at biannual R&D update
23 September 1999
Lescol cuts mortality in angioplasty patients
5 March 1999
Takeda entering new phase of global expansion, says MSDW analyst
18 February 1999
Novartis warned by FDA over Lescol advert
4 February 1999
Novartis 1998 sales down on forecasts
21 January 1999
Novartis FAME Study For Primary Prevention In Elderly
4 November 1998
Pharma Sales Give Novartis Boost
22 October 1998
Novartis Files For Trileptal In USA
6 October 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
Novartis First Half Sales Under Expectations
16 July 1998
First Operational Year Strong At Novartis
19 March 1998
Novartis' Nine-Month Drug Sales Climb 26%
30 October 1997
Strong Pharmaceutical Growth Drives Novartis
24 July 1997
Health Care Fuels Strong 1997 Start For Novartis
21 April 1997
First Launch Of Bayer's Lipobay
9 April 1997
1996 A Demanding Year For Novartis
19 March 1997
Lipitor To Drive Outperformance At W-L?
14 March 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Atorvastatin: 1st Approvals In UK And Germany
9 December 1996
Fluvastatin Slows CAD Development; LCAS
25 November 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
Tactical Diversity In The Evolving US Health Market
17 June 1996
....Nutrition Downturn And Currency Holds Sandoz Back
29 April 1996
Pipeline Contains Two Blockbusters, Says W-L
22 April 1996
Novartis Will Be A Leading Player In OTC Market
8 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Sales Growth For Sandoz In 1995
22 January 1996
US FTC "Must Monitor Company/PBM Deals"
20 November 1995
Sandoz 9 Months Sales up 6%
6 November 1995
Drug Sales Boost Sandoz In First Half 1995
4 September 1995
Sandoz Half-Year Sales Up 6%, But Pharma Down 2%
24 July 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Sandoz' 1994 Sales Advance 11%
23 January 1995
3% Increase In Sales For Sandoz
31 October 1994
Global Cardiovascular Market Growth Set To Slow
5 September 1994
Mixed Results From US Companies In 2nd Qtr
8 August 1994
SOLID VOLUME GROWTH HELPS SANDOZ' SALES
25 July 1994
MERCK/SANDOZ VIE FOR MARKET SHARE
27 June 1994
INDUSTRY WARNED OVER DECLINE OF DOCTOR ROLE
11 April 1994
NEW YORK STOCK COMMENT
4 April 1994
MERCK & CO FIGHTS BACK OVER LESCOL
4 April 1994
PRICE WAR LOOMING FOR HYPOLIPEMICS
28 March 1994
TOKYO STOCK COMMENT
28 March 1994
SANDOZ AND MMD IN COPROMOTION
28 February 1994
UK PRODUCT NEWS IN BRIEF
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
Showing 1-94 of 94 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
